Research programme: hepatitis C therapeutics - Dynavax

Drug Profile

Research programme: hepatitis C therapeutics - Dynavax

Alternative Names: Hepatitis C immunostimulatory DNA therapy

Latest Information Update: 18 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynavax Technologies
  • Developer Dynavax Technologies; Symphony Dynamo
  • Class Oligonucleotides
  • Mechanism of Action Th1 cell stimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 18 Apr 2012 No development reported - Preclinical for Hepatitis C in USA (unspecified route)
  • 16 Apr 2008 Preclinical trials in Hepatitis C in USA (unspecified route)
  • 26 Sep 2006 Early research in Hepatitis C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top